Clinical Trial

Cardiac Changes in Early Parkinson's Disease: A Follow up Study

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 2, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the long-term effects of treatment with the adrenergic blocker carvedilol on serial DaTscan, a dopamine transporter (DAT) single photon emission computerized tomography (SPECT) imaging technique in a population of subjects with defined pre-motor Parkinson's disease risks (i.e., REM sleep Behavior Disorder (RBD) and at least one among hyposmia, constipation, depression and color vision abnormality) and abnormal 123I-Metaiodobenzylguanidine (MIBG) scintigraphy.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-01-02; most recent amendment 2026-02-26.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-02-26
Trial Details
NCT Number NCT04218968
Lead Sponsor Cedars-Sinai Medical Center
Conditions REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Enrollment 15 participants
Start Date 2019-12-30
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-02